AI + RNA technology startup ReviR Therapeutics announced that it completed the pre-A financing with a total financing amount of tens of millions of dollars. This round of funds will be used to continue to promote the evaluation and verification of its voyageR™AI technology platform. By combining machine learning with advanced RNA biology R&D technology, ReviR will further accelerate the screening and development of its candidate compounds and lay a foundation for an extensive clinical application layout.

ReviR Therapeutics, founded in May 2021, is committed to the research and development of drugs targeting RNA driven by artificial intelligence algorithms and gene technology, so as to solve the long-term unmet clinical needs such as tumors, infections, and rare diseases.

In recent years, due to its unique advantages and broad prospects in the research of "non-druggable" targets, the research and development technology of small molecule drugs targeting RNA has attracted the attention of pharmaceutical enterprises. Compared with proteins, the development of high-throughput nucleic acid sequencing technology and super Moore's law makes it easier to digitize RNA.

ReviR and its core technical team focus on the calculation of RNA spatial structure, analyze the structure of RNA through algorithm and large-scale sequencing, and develop the "pocket" in the RNA structure of small molecule drugs, that is, its active site, so as to block the mechanisms such as shear translation. This will help to achieve the purpose of treating diseases and achieve a breakthrough in the "non-druggable" target at the protein level.